Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors

Nature Reviews Cancer

Volumn 6, Issue 8, 2006, Pages 613-625

  Muller, Alexander J ^a   Scherle, Peggy A ^b  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b Experimental Station   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(2 BORONOETHYL)CYSTEINE; 1 METHYL TRYPTOPHAN; 1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; AG 13736; AMINO 6 BORONOHEXANOIC ACID; ANTIINFECTIVE AGENT; AP 12009; ARGININE DERIVATIVE; BORONIC ACID DERIVATIVE; CELECOXIB; CP 533536; CPA 7; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC AGENT; IC 487892; INCB 3344; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; JSI 124; LY 580276; METHYLTHIOHYDANTOIN TRYPTOPHAN; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; PACLITAXEL; PROSTAGLANDIN RECEPTOR; PS 891169; ROFECOXIB; SB 505124; SD 208; SEMAXANIB; TRANSFORMING GROWTH FACTOR BETA; TRYPTOPHAN DERIVATIVE; TUMOR VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AUTOIMMUNITY; BIOLOGICAL ACTIVITY; BREAST CARCINOMA; CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER THERAPY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNE FUNCTION TEST; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; OVARY CANCER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; REVIEW; TUMOR IMMUNITY;

ANTINEOPLASTIC AGENTS; ARGINASE; CYCLOOXYGENASE 2 INHIBITORS; CYTOKINES; HUMANS; IMMUNE TOLERANCE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; NEOPLASMS; NITRIC OXIDE SYNTHASE; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 33746475270     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1929     Document Type: Review

References (142)

1. Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539-545 (2001).
2. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
3. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3, 991-998 (2002).
4. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Rev. Cancer 5, 263-274 (2005). Insightful review on the role of immune tolerance in tumour biology.
5. Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nature Med. 10, 909-915 (2004).
6. Mellor, A. L. & Munn, D. H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nature Rev. Immunol. 4, 762-774 (2004). Comprehensive review of IDO-mediated immune modulation.
7. Munn, D. H. et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281, 1191-1193 (1998). Landmark demonstration that IDO-inhibitor treatment promotes immune rejection of allogeneic concepti, establishing the physiological relevance of IDO to peripheral immune tolerance.
8. Munn, D. H. et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189, 1363-1372 (1999).
9. Burke, F., Knowles, R. G., East, N. & Balkwill, F. R. The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-γ in vivo. Int. J. Cancer 60, 115-122 (1995).
10. Ozaki, Y., Edelstein, M. P. & Duch, D. S. Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon γ. Proc. Natl Acad. Sci. USA 85, 1242-1246 (1988).
11. Uyttenhove, C. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Med. 9, 1269-1274 (2003).
12. Okamoto, A. et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin. Cancer Res. 11, 6030-6039 (2005).
13. Brandacher, C. et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin. Cancer Res. 12, 1144-1151 (2006).
14. Mellor, A. L., Keskin, D. B., Johnson, T., Chandler, P. & Munn, D. H. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J. Immunol. 168, 3771-3776 (2002).
15. Muller, A. J., Duhadaway, J. B., Donover, P. S., Sutanto-Ward, E. & Prendergast, G. C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nature Med. 11, 312-319 (2005).
16. Astigiano, S. et al. Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer. Neoplasia 7, 390-396 (2005).
17. Friberg, M. et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int. J. Cancer 101, 151-155 (2002).
18. Baban, B. et al. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int. Immunol. 17, 909-919 (2005).
19. Munn, D. H. et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest 114, 280-290 (2004).
20. Terness, P., Chuang, J. J. & Opelz, G. The immunoregulatory role of IDO-producing human dendritic cells revisited. Trends Immunol. 27, 68-73 (2006).
21. Mellor, A. L. et al. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int. Immunol. 16, 1391-1401 (2004).
22. Fallarino, F. et al. Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J. Immunol. 173, 3748-3754 (2004).
23. Fallarino, F. et al. Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells. Int. Immunol. 17, 1429-1438 (2005).
24. + dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN type 1 signaling. J. Immunol. 175, 5601-5605 (2005).
25. Wingender, G. et al. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur. J. Immunol. 36, 12-20 (2006).
26. Mellor, A. Indoleamine 2,3 dioxygenase and regulation of T cell immunity. Biochem. Biophys. Res. Commun. 338, 20-24 (2005).
27. Muller, A. J., Malachowski, W. P. & Prendergast, G. C. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin. Ther. Targets 9, 831-849 (2005).
28. Cady, S. G. & Sono, M. 1-methyl-DL-tryptophan, β-(3- benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and β-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch. Biochem. Biophys. 291, 326-333 (1991).
29. Munn, D. H. et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297, 1867-1870 (2002).
30. Malachowski, W. P., Metz, R., Prendergast, G. C. & Muller, A. J. A new cancer immunosuppression target: indoleamine 2,3-dioxygenase (IDO). A review of the IDO mechanism, inhibition and therapeutic applications. Drugs Fut. 30, 897 (2005).
31. Gaspari, P. et al. Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J. Med. Chem. 49, 684-692 (2006).
32. 2 incorporation by a heme-containing dioxygenase. Proc. Natl Acad. Sci. USA 103, 2611-2616 (2006).
33. Vottero, E. et al. Inhibitors of human indoleamine 2,3-dioxygenase identified with a target-based screen in yeast. Biotech. J. 1, 282-288 (2006).
34. Munn, D. H. et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22, 633-642 (2005).
35. Bronte, V. & Zanovello, P. Regulation of immune responses by L-arginine metabolism. Nature Rev. Immunol. 5, 641-654 (2005). Comprehensive review of arginase-mediated immune modulation.
36. Rodriguez, P. C. & Ochoa, A. C. T cell dysfunction in cancer: role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress. Semin. Cancer Biol. 16, 66-72 (2006).
37. O'Brien, T. G., Megosh, L. C., Gilliard, G. & Soler, A. P. Ornithine decarboxylase overexpression is a sufficient condition for tumor promotion in mouse skin. Cancer Res. 57, 2630-2637 (1997).
38. Gerner, E. W. & Meyskens, F. L. Jr. Polyamines and cancer: old molecules, new understanding. Nature Rev. Cancer 4, 781-792 (2004).
39. Singh, R., Pervin, S., Karimi, A., Cederbaum, S. & Chaudhuri, G. Arginase activity in human breast cancer cell lines: N(o)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res. 60, 3305-3312 (2000).
40. Kusmartsev, S. & Gabrilovich, D. I. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J. Immunol. 174, 4880-4891 (2005).
41. Rodriguez, P. C. et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64, 5839-5849 (2004).
42. Zea, A. H. et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65, 3044-3048 (2005). First demonstration of the potential role of arginase-producing MSCs in human cancer.
43. Chang, C. I., Liao, J. C. & Kuo, L. Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res. 61, 1100-1106 (2001).
44. Rodriguez, P. C. et al. Regulation of T cell receptor CD3ζ chain expression by L-arginine. J. Biol. Chem. 277, 21123-21129 (2002).
45. Lorsbach, R. B., Murphy, W. J., Lowenstein, C. J., Snyder, S. H. & Russell, S. W. Expression of the nitric oxide synthase gene in mouse macrophages activated for tumor cell killing. Molecular basis for the synergy between interferon-γ and lipopolysaccharide. J. Biol. Chem. 268, 1908-1913 (1993).
46. Mills, C. D., Shearer, J., Evans, R. & Caldwell, M. D. Macrophage arginine metabolism and the inhibition or stimulation of cancer. J. Immunol. 149, 2709-2714 (1992).
47. Bronte, V. et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J. Immunol. 170, 270-278 (2003).
48. Sonoki, T. et al. Coinduction of nitric-oxide synthase and arginase I in cultured rat peritoneal macrophages and rat tissues in vivo by lipopolysaccharide. J. Biol. Chem. 272, 3689-3693 (1997).
49. Mazzoni, A. et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 168, 689-695 (2002).
50. + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172, 989-999 (2004).
51. Bronte, V. et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J. Exp. Med. 201, 1257-1268 (2005).
52. De Santo, C. et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc. Natl Acad. Sci. USA 102, 4185-4190 (2005).
53. Moali, C. et al. Recognition of α-amino acids bearing various C = NOH functions by nitric oxide synthase and arginase involves very different structural determinants. Biochemistry 39, 8208-8218 (2000).
54. Di Costanzo, L. et al. Crystal structure of human arginase I at 1.29-Å-resolution and exploration of inhibition in the immune response. Proc. Natl Acad. Sci. USA 102, 13058-13063 (2005).
55. Colleluori, D. M. & Ash, D. E. Classical and slow-binding inhibitors of human type II arginase. Biochemistry 40, 9356-9362 (2001).
56. Cederbaum, S. D. et al. Arginases I and II: do their functions overlap? Mol. Genet. Metab. 81 (Suppl. 1), S38-S44 (2004).
57. Fiorucci, S. et al. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 124, 600-607 (2003).
58. Ensor, C. M., Holtsberg, F. W., Bomalaski, J. S. & Clark, M. A. Pegylated arginine deiminase (ADI-SS PEG 20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res. 62, 5443-5450 (2002).
59. Pereg, D. & Lishner, M. Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J. Intern. Med. 258, 115-123 (2005).
60. Dannenberg, A. J. et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2, 544-551 (2001).
61. Stolina, M. et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 164, 361-370 (2000). A pioneering study demonstrating that COX-2 inhibition can promote anti-tumour immunity in vivo.
62. DeLong, P. et al. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res. 63, 7845-7852 (2003).
63. Kundu, N., Walser, T. C., Ma, X. & Fulton, A. M. Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol. Immunother. 54, 981-987 (2005).
64. Morecki, S. et al. Induction of antitumor immunity by indomethacin. Cancer Immunol. Immunother. 48, 613-620 (2000).
65. Sharma, S. et al. Cyclooxygenase 2 inhibition promotes IFN-γ-dependent enhancement of antitumor responses. J. Immunol. 175, 813-819 (2005).
66. Zeytin, H. E. et al. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA. Tg/MIN mice. Cancer Res. 64, 3668-3678 (2004).
67. Pockaj, B. A. et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann. Surg. Oncol. 11, 328-339 (2004).
68. + T cells. J. Immunol. 175, 1483-1490 (2005).
69. + T regulatory cell activities in lung cancer. Cancer Res. 65, 5211-5220 (2005).
70. Braun, D., Longman, R. S. & Albert, M. L. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 106, 2375-2381 (2005).
71. Rodriguez, P. C. et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med. 202, 931-939 (2005).
72. Csiki, I. et al. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. Clin. Cancer Res. 11, 6634-6640 (2005).
73. Ferrari, V. et al. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. Cancer Chemother. Pharmacol. 57, 185-190 (2006).
74. Gasparini, G. et al. Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer. Oncologist 10, 710-717 (2005).
75. Gasparini, G. et al. The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates. Cancer J. 11, 209-216 (2005).
76. Nugent, F. W. et al. Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial. Lung Cancer 48, 267-273 (2005).
77. Krum, H., Liew, D., Aw, J. & Haas, S. Cardiovascular effects of selective cyclooxygenase-2 inhibitors. Expert Rev. Cardiovasc. Ther. 2, 265-270 (2004).
78. Yang, L. et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J. Clin. Invest. 111, 727-735 (2003).
79. Kennedy, C. R. et al. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nature Med. 5, 217-220 (1999).
80. Dumont, N. & Arteaga, C. L. Targeting the TGFβ signaling network in human neoplasia. Cancer Cell 3, 531-536 (2003).
81. Yingling, J. M., Blanchard, K. L. & Sawyer, J. S. Development of TGFβ signalling inhibitors for cancer therapy. Nature Rev. Drug Discov. 3, 1011-1022 (2004).
82. Herrmann, S. & Abdi, K. Both IL-2 and IL-4 synergize with IL-12 to induce a CTL response, a response completely blocked by TGFβ. Ann. NY Acad. Sci. 795, 168-180 (1996).
83. Torre-Amione, G. et al. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNAescapes immune surveillance. Proc. Natl Acad. Sci. USA 87, 1486-1490 (1990).
84. Kao, J. Y., Gong, Y., Chen, C. M., Zheng, Q. D. & Chen, J. J. Tumor-derived TGFβ reduces the efficacy of dendritic cell/tumor fusion vaccine. J. Immunol. 170, 3806-3811 (2003).
85. Gorelik, L. & Flavell, R. A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nature Med. 7, 1118-1122 (2001). Seminal work demonstrating that inhibition of TGFβ signaling enhances anti-tumour immunity in vivo through a T-cell-specific mechanism.
86. Gorelik, L., Constant, S. & Flavell, R. A. Mechanism of transforming growth factor β-induced inhibition of T helper type 1 differentiation. J. Exp. Med. 195, 1499-1505 (2002).
87. Gorelik, L., Fields, P. E. & Flavell, R. A. Cutting edge: TGFβ inhibits Th type 2 development through inhibition of GATA-3 expression. J. Immunol. 165, 4773-4777 (2000).
88. Laouar, Y., Sutterwala, F. S., Gorelik, L. & Flavell, R. A. Transforming growth factor-β controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nature Immunol. 6, 600-607 (2005).
89. Strobl, H. & Knapp, W. TGF-β1 regulation of dendritic cells. Microbes Infect. 1, 1283-1290 (1999).
90. + regulatory cells that control intestinal inflammation. J. Exp. Med. 192, 295-302 (2000).
91. - thymocytes. J. Exp, Med. 189, 279-288 (1999).
92. + regulatory T cells can mediate suppressor function in the absence of transforming growth factor β1 production and responsiveness. J. Exp. Med. 196, 237-246 (2002).
93. + regulatory T cells. J. Exp. Med. 201, 1061-1067 (2005).
94. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198, 1875-1886 (2003).
95. Lahn, M., Kloeker, S. & Berry, B. S. TGF-β inhibitors for the treatment of cancer. Expert. Opin. Investig. Drugs 14, 629-643 (2005).
96. Uhl, M. et al. SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64, 7954-7961 (2004).
97. Rawlings, J. S., Rosler, K. M. & Harrison, D. A. The JAK/STAT signaling pathway. J. Cell Sci. 117, 1281-1283 (2004).
98. Langowski, J. L. et al. IL-23 promotes tumour incidence and growth. Nature 10 May 2006 (doi:10.1038/nature04808).
99. Wang, T. et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nature Med. 10, 48-54 (2004). First demonstration on the role of STAT3 in modulating anti-tumour immunity by inhibiting production of pro-inflammatory cytokines.
100. Burdelya, L. et al. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J. Immunol. 174, 3925-3931 (2005).
101. Blaskovich, M. A. et al. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 63, 1270-1279 (2003).
102. Nefedova, Y. et al. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J. Immunol. 175, 4338-4346 (2005).
103. Nefedova, Y. et al. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 65, 9525-9535 (2005).
104. Kortylewski, M. et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nature Med. 11, 1314-1321 (2005).
105. Terabe, M. et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nature Immunol. 1, 515-520 (2000).
106. Kacha, A. K., Fallarino, F., Markiewicz, M. A. & Gajewski, T. F. Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J. Immunol. 165, 6024-6028 (2000).
107. Ostrand-Rosenberg, S., Grusby, M. J. & Clements, V. K. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J. Immunol. 165, 6015-6019 (2000).
108. Ostrand-Rosenberg, S. et al. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-γ dependent. J. Immunol. 169, 5796-5804 (2002).
109. Sinha, P., Clements, V. K. & Ostrand-Rosenberg, S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 174, 636-645 (2005).
110. O'Shea, J. J., Park, H., Pesu, M., Borie, D. & Changelian, P. New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway. Curr. Opin. Rheumatol. 17, 305-311 (2005).
111. Ferrara, N., Hillan, K. J. & Novotny, W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 333, 328-335 (2005).
112. Almand, B. et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 6, 1755-1766 (2000).
113. Gabrilovich, D. et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92, 4150-4166 (1998).
114. Gabrilovich, D. I. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med. 2, 1096-1103 (1996). Pioneering study demonstrating that VEGF can modulate anti-tumour immunity by preventing DC maturation.
115. Gabrilovich, D. I., Ishida, T., Nadaf, S., Ohm, J. E. & Carbone, D. P. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 5, 2963-2970 (1999).
116. Dikov, M. M. et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J. Immunol. 174, 215-222 (2005).
117. Oyama, T. et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in hemopoietic progenitor cells. J. Immunol. 160, 1224-1232 (1998).
118. Homey, B., Muller, A. & Zlotnik, A. Chemokines: agents for the immunotherapy of cancer? Nature Rev. Immunol. 2, 175-184 (2002).
119. reg cells is associated with poor prognosis in ovarian cancer.
120. + regulatory T cells. J. Exp. Med. 194, 847-853 (2001).
121. + T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J. Exp. Med. 201, 1037-1044 (2005).
122. Kuroda, E., Sugiura, T., Okada, K., Zeki, K. & Yamashita, U. Prostaglandin E2 up-regulates macrophage-derived chemokine production but suppresses IFN-inducible protein-10 production by APC. J. Immunol. 166, 1650-1658 (2001).
123. Zou, W. et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nature Med. 7, 1339-1346 (2001).
124. Ueno, T. et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 6, 3282-3289 (2000).
125. Balkwill, F. Cancer and the chemokine network. Nature Rev. Cancer 4, 540-550 (2004).
126. Lake, R. A. & Robinson, B. W. Opinion: immunotherapy and chemotherapy - a practical partnership. Nature Rev. Cancer 5, 397-405 (2005).
127. Mokyr, M. B., Kalinichenko, T., Gorelik, L. & Bluestone, J. A. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res. 58, 5301-5304 (1998).
128. de Gramont, A. & Van Cutsem, E. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 69 (Suppl. 3), 46-56 (2005).
129. Meric, J. B. et al. Cyclooxygenase-2 as a target for anticancer drug development. Crit. Rev. Oncol. Hematol. 59, 51-64 (2006).
130. van der Most, R. G., Currie, A., Robinson, B. W. & Lake, R. A. Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. Cancer Res. 66, 601-604 (2006).
131. Emens, L. A. & Jaffee, E. M. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res. 65, 8059-8064 (2005).
132. Muller, A. J. & Prendergast, G. C. Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res. 65, 8065-8068 (2005).
133. Freeman, B. D., Danner, R. L., Banks, S. M. & Natanson, C. Safeguarding patients in clinical trials with high mortality rates. Am. J. Respir. Crit. Care Med. 164, 190-192 (2001).
134. Warner, T. D. & Mitchell, J. A. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 18, 790-804 (2004).
135. Haas, A. R. et al. Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin. Cancer Res. 12, 214-222 (2006).
136. DaCosta Byfield, S., Major, C., Laping, N. J. & Roberts, A. B. SB-505124 is a selective inhibitor of transforming growth factor-β type I receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 65, 744-752 (2004).
137. Yi, J. Y., Shin, I. & Arteaga, C. L. Type I transforming growth factor β receptor binds to and activates phosphatidylinositol 3-kinase. J. Biol. Chem. 280, 10870-10876 (2005).
138. Turkson, J. et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol. Cancer Ther. 3, 1533-1542 (2004).
139. Itokawa, T. et al. Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling. Mol. Cancer. Ther. 1, 295-302 (2002).
140. DeClercq, E. The bicyclam AMD3100 story. Nature Rev. Drug Discov. 2, 581-587 (2003).
141. Brodmerkel, C. M. et al. Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. J. Immunol. 175, 5370-5378 (2005).
142. Fallarino, F. et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and incude a regulatory phenotype in naive cells. J. Immunol. 176, 6752-6761 (2006).